Dutch health technology startup Aiosyn has raised €2 million (approximately $2.1 million) in funding to improve clinical diagnostics using artificial intelligence.
CEO and co-founder Patrick de Boer said the health industry was facing the challenges of higher workload and staff shortage. This issue caused slow development in finding cures for several diseases, including cancer. Another difficulty in the field is the slow diagnosis processes. For many patients, efficient diagnostics are vital.
Founded in 2021, the Dutch startup helps pathologists diagnose patients more efficiently. Aiosyn’s technology deals with labor-intensive, routine pathology tasks, allowing pathologists to focus on the more complex part of the job.
Health Innovations led the funding round. The firm’s investment manager, Yvonne Sijm, said the future of healthcare would rely on digital innovations. Sijm added that Aiosyn’s technology could help address the issues prevalent in the industry.
Oost NL and LUMO Labs participated in the round. Björn Schaap, an investment manager at Oost NL, said Aiosyn’s technology could break the boundaries within pathology.
“The tremendous development Aiosyn has made in the last year solidifies this belief, and for this reason, the company has the support of Oost NL,” Schaap added.
LUMO partner Sven Bakkes said the healthcare industry experienced an uptake in 2022, and Aiosyn had recorded significant milestones this year. He explained that the fund would help Aiosyn “take the essential next steps” to be more impactful.
Aiosyn aims to speed up its launch with the funding. The startup has started developing two algorithms to help improve the accuracy of diagnostics. Earlier this year, Aiosyn also received the ISO:13485 certification.
Aiosyn co-founders developed the startup as a spin-off to the Radboud University Medical Center’s Computational Pathology research group, which is one of the best programs within the field. The startup builds its technology based on the program’s decades of research.
